Annabelle Volgman
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 19 | 2021 | 193 | 7.610 |
Why?
| Cardiovascular Diseases | 16 | 2021 | 391 | 4.420 |
Why?
| Stroke | 18 | 2021 | 345 | 4.040 |
Why?
| Healthcare Disparities | 6 | 2020 | 79 | 2.060 |
Why?
| Anticoagulants | 5 | 2016 | 147 | 1.980 |
Why?
| Heart Failure | 6 | 2021 | 231 | 1.920 |
Why?
| Sex Factors | 17 | 2021 | 535 | 1.870 |
Why?
| Female | 66 | 2021 | 18107 | 1.860 |
Why?
| Humans | 81 | 2021 | 30741 | 1.690 |
Why?
| Coronary Artery Disease | 6 | 2020 | 154 | 1.650 |
Why?
| Risk Factors | 27 | 2021 | 2611 | 1.570 |
Why?
| Exercise | 6 | 2020 | 431 | 1.510 |
Why?
| Hospital Mortality | 6 | 2021 | 187 | 1.500 |
Why?
| Myocardial Infarction | 8 | 2021 | 191 | 1.490 |
Why?
| Hospitalization | 8 | 2021 | 344 | 1.480 |
Why?
| Life Style | 8 | 2020 | 208 | 1.470 |
Why?
| Women's Health | 4 | 2020 | 220 | 1.460 |
Why?
| Cardiology | 4 | 2021 | 99 | 1.400 |
Why?
| Risk Assessment | 13 | 2021 | 804 | 1.360 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 75 | 1.300 |
Why?
| Sex Characteristics | 5 | 2021 | 126 | 1.260 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 30 | 1.180 |
Why?
| Primary Prevention | 3 | 2020 | 43 | 1.180 |
Why?
| Adrenergic beta-Antagonists | 2 | 2020 | 45 | 1.170 |
Why?
| Health Status Disparities | 4 | 2019 | 68 | 1.160 |
Why?
| Aged | 36 | 2021 | 10156 | 1.160 |
Why?
| Arrhythmias, Cardiac | 6 | 2019 | 169 | 1.140 |
Why?
| Defibrillators, Implantable | 3 | 2021 | 38 | 1.110 |
Why?
| Physicians, Women | 2 | 2021 | 14 | 1.100 |
Why?
| Male | 40 | 2021 | 17552 | 1.040 |
Why?
| Myocardial Ischemia | 2 | 2021 | 62 | 1.030 |
Why?
| Catheter Ablation | 2 | 2020 | 78 | 1.020 |
Why?
| United States | 23 | 2021 | 2467 | 1.000 |
Why?
| American Heart Association | 3 | 2021 | 35 | 1.000 |
Why?
| Echocardiography, Doppler, Color | 2 | 2019 | 15 | 0.990 |
Why?
| Middle Aged | 30 | 2021 | 11256 | 0.930 |
Why?
| Coronavirus | 1 | 2021 | 4 | 0.910 |
Why?
| Pregnancy Complications, Cardiovascular | 5 | 2021 | 16 | 0.910 |
Why?
| Electrocardiography | 7 | 2015 | 231 | 0.890 |
Why?
| Breast Neoplasms | 3 | 2021 | 440 | 0.880 |
Why?
| Length of Stay | 4 | 2020 | 371 | 0.850 |
Why?
| Chest Pain | 1 | 2020 | 23 | 0.850 |
Why?
| Social Media | 1 | 2021 | 32 | 0.840 |
Why?
| Endothelium | 1 | 2020 | 15 | 0.840 |
Why?
| Patient Care Management | 2 | 2021 | 16 | 0.810 |
Why?
| Brain Ischemia | 1 | 2021 | 117 | 0.810 |
Why?
| Anti-Arrhythmia Agents | 5 | 2020 | 105 | 0.800 |
Why?
| Vascular Diseases | 1 | 2020 | 58 | 0.800 |
Why?
| Quality of Life | 4 | 2020 | 636 | 0.790 |
Why?
| Takotsubo Cardiomyopathy | 1 | 2019 | 20 | 0.790 |
Why?
| Myxoma | 1 | 2019 | 7 | 0.790 |
Why?
| Cardiomyopathies | 1 | 2019 | 37 | 0.780 |
Why?
| Heart Neoplasms | 1 | 2019 | 21 | 0.780 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.770 |
Why?
| Women's Health Services | 1 | 2018 | 12 | 0.760 |
Why?
| Comorbidity | 5 | 2021 | 562 | 0.750 |
Why?
| Culturally Competent Care | 1 | 2018 | 10 | 0.740 |
Why?
| Heart Diseases | 1 | 2020 | 102 | 0.740 |
Why?
| Ambulatory Care Facilities | 1 | 2018 | 41 | 0.730 |
Why?
| Age Factors | 8 | 2021 | 941 | 0.730 |
Why?
| Delivery of Health Care, Integrated | 1 | 2018 | 30 | 0.730 |
Why?
| Prevalence | 6 | 2020 | 546 | 0.730 |
Why?
| Emigrants and Immigrants | 1 | 2018 | 25 | 0.720 |
Why?
| Atherosclerosis | 1 | 2018 | 48 | 0.720 |
Why?
| Warfarin | 3 | 2016 | 61 | 0.710 |
Why?
| Coronavirus Infections | 1 | 2020 | 97 | 0.710 |
Why?
| Pneumonia, Viral | 1 | 2020 | 104 | 0.710 |
Why?
| Heart Ventricles | 1 | 2019 | 220 | 0.710 |
Why?
| Antineoplastic Agents | 1 | 2020 | 321 | 0.660 |
Why?
| Lipoprotein(a) | 1 | 2016 | 10 | 0.630 |
Why?
| Dyslipidemias | 1 | 2016 | 24 | 0.620 |
Why?
| Cognition | 3 | 2020 | 1141 | 0.620 |
Why?
| Electrodes | 1 | 2015 | 17 | 0.600 |
Why?
| Prognosis | 7 | 2021 | 1045 | 0.600 |
Why?
| Cost of Illness | 1 | 2015 | 65 | 0.580 |
Why?
| Treatment Outcome | 11 | 2020 | 3850 | 0.570 |
Why?
| Social Support | 1 | 2016 | 217 | 0.560 |
Why?
| Electric Countershock | 6 | 2020 | 30 | 0.530 |
Why?
| Patient Readmission | 3 | 2019 | 124 | 0.530 |
Why?
| Aspirin | 2 | 2020 | 89 | 0.530 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 228 | 0.520 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 1244 | 0.510 |
Why?
| Aged, 80 and over | 9 | 2021 | 5172 | 0.500 |
Why?
| Patient Acceptance of Health Care | 1 | 2012 | 83 | 0.460 |
Why?
| Coronary Angiography | 3 | 2020 | 106 | 0.450 |
Why?
| Adult | 13 | 2020 | 9760 | 0.440 |
Why?
| Cardiovascular System | 2 | 2021 | 10 | 0.430 |
Why?
| Acute Kidney Injury | 2 | 2021 | 59 | 0.420 |
Why?
| Pregnancy | 6 | 2021 | 452 | 0.410 |
Why?
| Cardiac Resynchronization Therapy Devices | 2 | 2019 | 10 | 0.410 |
Why?
| Cardiovascular Agents | 2 | 2021 | 34 | 0.410 |
Why?
| Transcatheter Aortic Valve Replacement | 2 | 2020 | 27 | 0.410 |
Why?
| Aortic Valve Stenosis | 2 | 2020 | 29 | 0.410 |
Why?
| Hospital Costs | 2 | 2020 | 74 | 0.390 |
Why?
| Feasibility Studies | 2 | 2020 | 283 | 0.390 |
Why?
| Diabetes Mellitus | 2 | 2020 | 140 | 0.380 |
Why?
| Practice Guidelines as Topic | 3 | 2021 | 389 | 0.350 |
Why?
| Secondary Prevention | 2 | 2018 | 64 | 0.350 |
Why?
| Ventricular Fibrillation | 2 | 2021 | 35 | 0.350 |
Why?
| Heart Atria | 2 | 2019 | 95 | 0.340 |
Why?
| Retrospective Studies | 8 | 2021 | 3456 | 0.340 |
Why?
| Hypertension | 5 | 2020 | 272 | 0.340 |
Why?
| Administration, Oral | 3 | 2016 | 165 | 0.300 |
Why?
| Health Status | 2 | 2018 | 252 | 0.300 |
Why?
| Sex Distribution | 3 | 2019 | 91 | 0.300 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2020 | 361 | 0.300 |
Why?
| Hemorrhage | 5 | 2020 | 88 | 0.290 |
Why?
| Antihypertensive Agents | 2 | 2020 | 91 | 0.280 |
Why?
| Risk Adjustment | 2 | 2021 | 14 | 0.280 |
Why?
| African Americans | 3 | 2016 | 780 | 0.270 |
Why?
| Hospital Charges | 2 | 2020 | 23 | 0.270 |
Why?
| Incidence | 4 | 2020 | 827 | 0.270 |
Why?
| Logistic Models | 3 | 2021 | 479 | 0.270 |
Why?
| Obesity | 4 | 2020 | 322 | 0.260 |
Why?
| Aortic Valve | 2 | 2020 | 34 | 0.260 |
Why?
| Illinois | 2 | 2021 | 268 | 0.260 |
Why?
| Cardiotoxicity | 2 | 2020 | 9 | 0.260 |
Why?
| Age Distribution | 2 | 2020 | 116 | 0.260 |
Why?
| Morbidity | 2 | 2019 | 71 | 0.250 |
Why?
| Young Adult | 3 | 2020 | 2249 | 0.250 |
Why?
| Health Promotion | 2 | 2016 | 183 | 0.240 |
Why?
| Cardiac Electrophysiology | 1 | 2021 | 3 | 0.240 |
Why?
| Coronary Circulation | 2 | 2020 | 49 | 0.230 |
Why?
| Troponin | 1 | 2021 | 11 | 0.230 |
Why?
| Shock, Cardiogenic | 1 | 2021 | 11 | 0.230 |
Why?
| Diagnostic Techniques, Cardiovascular | 1 | 2021 | 3 | 0.230 |
Why?
| Societies, Medical | 2 | 2020 | 203 | 0.230 |
Why?
| Sexism | 1 | 2021 | 8 | 0.230 |
Why?
| Water-Electrolyte Imbalance | 1 | 2021 | 3 | 0.230 |
Why?
| Hormones | 1 | 2021 | 19 | 0.230 |
Why?
| Death, Sudden, Cardiac | 1 | 2021 | 28 | 0.230 |
Why?
| Women's Rights | 1 | 2021 | 3 | 0.220 |
Why?
| Adolescent | 2 | 2020 | 2627 | 0.220 |
Why?
| National Institutes of Health (U.S.) | 1 | 2021 | 33 | 0.220 |
Why?
| Angioplasty | 1 | 2020 | 16 | 0.220 |
Why?
| Pacemaker, Artificial | 2 | 2019 | 48 | 0.220 |
Why?
| Signal Processing, Computer-Assisted | 2 | 1998 | 44 | 0.220 |
Why?
| Health Expenditures | 1 | 2020 | 20 | 0.220 |
Why?
| Hyperlipidemias | 1 | 2020 | 27 | 0.220 |
Why?
| Career Choice | 1 | 2021 | 32 | 0.220 |
Why?
| Cross-Sectional Studies | 4 | 2017 | 957 | 0.220 |
Why?
| Physician-Patient Relations | 1 | 2021 | 47 | 0.220 |
Why?
| Peripheral Arterial Disease | 1 | 2020 | 20 | 0.220 |
Why?
| Heart Valve Diseases | 1 | 2020 | 33 | 0.220 |
Why?
| Periodicals as Topic | 1 | 2021 | 42 | 0.220 |
Why?
| Postoperative Hemorrhage | 1 | 2020 | 30 | 0.210 |
Why?
| Disease Outbreaks | 1 | 2021 | 89 | 0.210 |
Why?
| Myocardial Revascularization | 1 | 2020 | 25 | 0.210 |
Why?
| Postnatal Care | 1 | 2020 | 9 | 0.210 |
Why?
| Delivery, Obstetric | 1 | 2020 | 15 | 0.210 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 4 | 0.210 |
Why?
| Colchicine | 1 | 2020 | 9 | 0.210 |
Why?
| Protective Factors | 1 | 2020 | 18 | 0.210 |
Why?
| Leadership | 1 | 2021 | 100 | 0.210 |
Why?
| Social Class | 1 | 2020 | 72 | 0.210 |
Why?
| After-Hours Care | 1 | 2019 | 1 | 0.200 |
Why?
| Income | 1 | 2020 | 71 | 0.200 |
Why?
| Endovascular Procedures | 1 | 2020 | 78 | 0.200 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2020 | 46 | 0.200 |
Why?
| Odds Ratio | 2 | 2020 | 328 | 0.200 |
Why?
| Prostatic Neoplasms | 1 | 2021 | 141 | 0.200 |
Why?
| Global Health | 1 | 2019 | 57 | 0.200 |
Why?
| Radiation Injuries | 1 | 2020 | 44 | 0.200 |
Why?
| Thrombolytic Therapy | 1 | 2020 | 84 | 0.200 |
Why?
| Up-Regulation | 2 | 2021 | 218 | 0.200 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2019 | 23 | 0.200 |
Why?
| Multimodal Imaging | 1 | 2019 | 30 | 0.200 |
Why?
| Health Behavior | 1 | 2020 | 175 | 0.190 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 386 | 0.190 |
Why?
| Treatment Refusal | 1 | 2018 | 14 | 0.190 |
Why?
| Heart | 1 | 2019 | 110 | 0.190 |
Why?
| Asia, Western | 1 | 2018 | 2 | 0.190 |
Why?
| Indian Ocean Islands | 1 | 2018 | 2 | 0.190 |
Why?
| Procainamide | 1 | 1998 | 24 | 0.190 |
Why?
| Intensive Care Units | 1 | 2021 | 300 | 0.180 |
Why?
| Heart Transplantation | 1 | 1998 | 52 | 0.180 |
Why?
| Pandemics | 1 | 2020 | 157 | 0.180 |
Why?
| Atrial Flutter | 1 | 1998 | 24 | 0.180 |
Why?
| Graft Rejection | 1 | 1998 | 85 | 0.180 |
Why?
| Walking | 1 | 2020 | 241 | 0.180 |
Why?
| Sulfonamides | 1 | 1998 | 66 | 0.180 |
Why?
| Reproducibility of Results | 3 | 2017 | 875 | 0.180 |
Why?
| Memory Disorders | 1 | 2019 | 180 | 0.170 |
Why?
| Inpatients | 1 | 2019 | 147 | 0.170 |
Why?
| Diagnosis, Differential | 1 | 2019 | 469 | 0.170 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 190 | 0.170 |
Why?
| Coronary Disease | 2 | 2020 | 103 | 0.170 |
Why?
| Diet Surveys | 1 | 2017 | 24 | 0.170 |
Why?
| Pyridones | 1 | 2016 | 18 | 0.170 |
Why?
| Patient Discharge | 1 | 2018 | 160 | 0.170 |
Why?
| Nutrition Assessment | 1 | 2017 | 53 | 0.170 |
Why?
| Thiazoles | 1 | 2016 | 39 | 0.170 |
Why?
| Evidence-Based Practice | 1 | 2017 | 82 | 0.170 |
Why?
| Pyridines | 1 | 2016 | 48 | 0.160 |
Why?
| Neoplasms | 1 | 2020 | 275 | 0.160 |
Why?
| Evidence-Based Medicine | 1 | 2018 | 239 | 0.160 |
Why?
| Georgia | 1 | 2016 | 16 | 0.160 |
Why?
| Patient Selection | 2 | 2020 | 259 | 0.160 |
Why?
| Diet, Mediterranean | 1 | 2017 | 53 | 0.160 |
Why?
| Cholesterol, LDL | 1 | 2016 | 44 | 0.160 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 594 | 0.160 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2016 | 64 | 0.160 |
Why?
| Pyrazoles | 1 | 2016 | 55 | 0.160 |
Why?
| Health Surveys | 1 | 2016 | 101 | 0.150 |
Why?
| Self Efficacy | 1 | 2016 | 62 | 0.150 |
Why?
| Miniaturization | 1 | 2015 | 3 | 0.150 |
Why?
| Preventive Health Services | 1 | 2015 | 15 | 0.150 |
Why?
| Equipment Design | 2 | 2015 | 204 | 0.150 |
Why?
| Asian Americans | 1 | 2015 | 53 | 0.150 |
Why?
| Chicago | 2 | 2016 | 945 | 0.150 |
Why?
| Equipment Failure Analysis | 1 | 2015 | 117 | 0.140 |
Why?
| Heart Rate | 2 | 2009 | 165 | 0.140 |
Why?
| Smoking | 2 | 2018 | 197 | 0.130 |
Why?
| Needs Assessment | 1 | 2013 | 50 | 0.130 |
Why?
| Cardiac Pacing, Artificial | 2 | 1992 | 81 | 0.130 |
Why?
| Drug Monitoring | 1 | 2012 | 28 | 0.120 |
Why?
| Activities of Daily Living | 1 | 2016 | 472 | 0.120 |
Why?
| Heart Conduction System | 1 | 1992 | 36 | 0.120 |
Why?
| Tachycardia | 1 | 1992 | 50 | 0.120 |
Why?
| Data Collection | 1 | 2012 | 118 | 0.120 |
Why?
| Echocardiography | 3 | 2019 | 201 | 0.100 |
Why?
| Percutaneous Coronary Intervention | 2 | 2020 | 24 | 0.100 |
Why?
| Coronary Vessels | 1 | 1990 | 51 | 0.100 |
Why?
| Motor Activity | 1 | 2013 | 395 | 0.100 |
Why?
| Coronary Artery Bypass | 2 | 2020 | 76 | 0.100 |
Why?
| Survival Rate | 2 | 2019 | 478 | 0.090 |
Why?
| Databases, Factual | 2 | 2019 | 372 | 0.080 |
Why?
| Azetidines | 1 | 2006 | 4 | 0.080 |
Why?
| Benzylamines | 1 | 2006 | 15 | 0.080 |
Why?
| Body Mass Index | 2 | 2020 | 438 | 0.080 |
Why?
| Severity of Illness Index | 2 | 2021 | 1233 | 0.080 |
Why?
| Time Factors | 3 | 2021 | 1911 | 0.070 |
Why?
| Endpoint Determination | 1 | 2004 | 31 | 0.070 |
Why?
| Cohort Studies | 2 | 2019 | 1959 | 0.060 |
Why?
| Postoperative Complications | 2 | 2020 | 1084 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2019 | 2046 | 0.060 |
Why?
| Double-Blind Method | 2 | 2006 | 550 | 0.060 |
Why?
| Prospective Studies | 2 | 1998 | 1891 | 0.060 |
Why?
| Peripartum Period | 1 | 2021 | 3 | 0.060 |
Why?
| Pregnancy, High-Risk | 1 | 2021 | 3 | 0.060 |
Why?
| Chlorides | 1 | 2021 | 27 | 0.060 |
Why?
| Diuretics | 1 | 2021 | 16 | 0.060 |
Why?
| Recurrence | 2 | 2006 | 390 | 0.060 |
Why?
| Health Services Research | 1 | 2021 | 45 | 0.060 |
Why?
| Sodium | 1 | 2021 | 77 | 0.050 |
Why?
| Amputation | 1 | 2020 | 20 | 0.050 |
Why?
| Education, Medical | 1 | 2021 | 45 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 75 | 0.050 |
Why?
| Patient Preference | 1 | 2021 | 34 | 0.050 |
Why?
| Abortion, Spontaneous | 1 | 2020 | 9 | 0.050 |
Why?
| Fetal Growth Retardation | 1 | 2020 | 4 | 0.050 |
Why?
| Polycystic Ovary Syndrome | 1 | 2020 | 5 | 0.050 |
Why?
| Hypercholesterolemia | 1 | 2020 | 38 | 0.050 |
Why?
| Menopause, Premature | 1 | 2020 | 7 | 0.050 |
Why?
| Ischemic Attack, Transient | 1 | 2020 | 27 | 0.050 |
Why?
| Sleep Apnea, Central | 1 | 2000 | 25 | 0.050 |
Why?
| Lactation | 1 | 2021 | 76 | 0.050 |
Why?
| Health Care Costs | 1 | 2020 | 82 | 0.050 |
Why?
| Case-Control Studies | 2 | 2000 | 694 | 0.050 |
Why?
| Radiotherapy | 1 | 2020 | 68 | 0.050 |
Why?
| Attitude to Health | 1 | 2020 | 116 | 0.050 |
Why?
| Curriculum | 1 | 2021 | 153 | 0.050 |
Why?
| Autoimmune Diseases | 1 | 2020 | 64 | 0.050 |
Why?
| Costs and Cost Analysis | 1 | 2019 | 39 | 0.050 |
Why?
| Cause of Death | 1 | 2019 | 74 | 0.050 |
Why?
| Thrombectomy | 1 | 2019 | 50 | 0.050 |
Why?
| Multivariate Analysis | 1 | 2020 | 391 | 0.050 |
Why?
| Disease Management | 1 | 2020 | 149 | 0.050 |
Why?
| Psychology | 1 | 2018 | 24 | 0.050 |
Why?
| Health Services Needs and Demand | 1 | 2018 | 69 | 0.050 |
Why?
| Blood Pressure | 1 | 2020 | 250 | 0.050 |
Why?
| Heredity | 1 | 2018 | 8 | 0.050 |
Why?
| Diet, Western | 1 | 2017 | 6 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2020 | 222 | 0.040 |
Why?
| Quality Improvement | 1 | 2018 | 169 | 0.040 |
Why?
| Breast Feeding | 1 | 2018 | 166 | 0.040 |
Why?
| Waist Circumference | 1 | 2015 | 34 | 0.040 |
Why?
| Body Composition | 1 | 2016 | 77 | 0.040 |
Why?
| Risk | 1 | 2016 | 232 | 0.040 |
Why?
| Decision Making | 1 | 2018 | 228 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 266 | 0.040 |
Why?
| Body Weight | 1 | 2016 | 165 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 473 | 0.040 |
Why?
| Patient Compliance | 1 | 2016 | 201 | 0.030 |
Why?
| Wolff-Parkinson-White Syndrome | 1 | 1993 | 4 | 0.030 |
Why?
| Dextroamphetamine | 1 | 1993 | 6 | 0.030 |
Why?
| Social Networking | 1 | 2013 | 10 | 0.030 |
Why?
| Syncope | 1 | 1993 | 10 | 0.030 |
Why?
| Hypotension, Orthostatic | 1 | 1993 | 17 | 0.030 |
Why?
| Efficiency | 1 | 2013 | 21 | 0.030 |
Why?
| Albuterol | 1 | 1993 | 17 | 0.030 |
Why?
| Bradycardia | 1 | 1993 | 33 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2013 | 146 | 0.030 |
Why?
| Interviews as Topic | 1 | 2013 | 148 | 0.030 |
Why?
| Program Evaluation | 1 | 2013 | 152 | 0.030 |
Why?
| Tachycardia, Ventricular | 1 | 1992 | 39 | 0.030 |
Why?
| Cardiac Catheterization | 1 | 1992 | 115 | 0.030 |
Why?
| Asthma | 1 | 1993 | 179 | 0.030 |
Why?
| Animals | 1 | 2020 | 5221 | 0.030 |
Why?
| Estrogen Replacement Therapy | 1 | 2006 | 22 | 0.020 |
Why?
| Thromboembolism | 1 | 2006 | 38 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 181 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2006 | 385 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2004 | 473 | 0.020 |
Why?
| Electrocardiography, Ambulatory | 1 | 2000 | 23 | 0.010 |
Why?
| Bronchoscopy | 1 | 2000 | 38 | 0.010 |
Why?
| Anesthesia | 1 | 2000 | 27 | 0.010 |
Why?
| Respiration | 1 | 2000 | 36 | 0.010 |
Why?
| Tracheostomy | 1 | 2000 | 27 | 0.010 |
Why?
| Child | 1 | 2000 | 1547 | 0.010 |
Why?
| False Positive Reactions | 1 | 1993 | 40 | 0.010 |
Why?
| Administration, Inhalation | 1 | 1993 | 36 | 0.010 |
Why?
| Posture | 1 | 1993 | 88 | 0.010 |
Why?
| Action Potentials | 1 | 1993 | 141 | 0.010 |
Why?
| ROC Curve | 1 | 1992 | 155 | 0.010 |
Why?
| Analysis of Variance | 1 | 1992 | 369 | 0.010 |
Why?
| Registries | 1 | 1991 | 203 | 0.010 |
Why?
|
|
Volgman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|